Ngā hua rapu - Quan Man
- E whakaatu ana i te 1 - 3 hua o te 3
-
1
Prognostic significance of grade of malignancy based on histopathological differentiation and Ki-67 in pancreatic ductal adenocarcinoma mā Yuexiang Liang, Guannan Sheng, Yu Guo, Yiping Zou, Hanhan Guo, Zhifei Li, Shaofei Chang, Quan Man, Song Gao, Jihui Hao
I whakaputaina 2024Artigo -
2
First‐In‐Human, First‐In‐Class, Phase I Trial of the Fucosylation Inhibitor SGN‐2FF in Patients with Advanced Solid Tumors mā Do, Khanh T., Chow, Laura Quan Man, Reckamp, Karen, Sanborn, Rachel E., Burris, Howard, Robert, Francisco, Camidge, D. Ross, Steuer, Conor E., Strickler, John H., Weise, Amy, Specht, Jennifer M., Gutierrez, Martin, Haughney, Peter, Hengel, Shawna, Derleth, Christina Louise, Yap, Timothy A.
I whakaputaina 2021Text -
3
Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis mā Tianxing Zhou, Yongjie Xie, Xupeng Hou, Weiwei Bai, Xueyang Li, Ziyun Liu, Quan Man, Jingyan Sun, Danqi Fu, Jingrui Yan, Zhaoyu Zhang, Yifei Wang, Hongwei Wang, Wenna Jiang, Song Gao, Tiansuo Zhao, Antao Chang, Xiuchao Wang, Hongxia Sun, Xiufeng Zhang, Shengyu Yang, Chongbiao Huang, Jihui Hao, Jing Liu
I whakaputaina 2023Artigo
Ngā utauta rapu:
Ngā marau whai pānga
Biology
Cancer
Internal medicine
Medicine
Adenocarcinoma
Biochemistry
Blood pressure
Cancer research
Clinical significance
Ecology
Gemcitabine
Gene
Grading (engineering)
Immunohistochemistry
Irbesartan
Ki-67
Malignancy
Oncology
Paleontology
Pancreatic cancer
Pancreatic ductal adenocarcinoma
Pathology
Pharmacology
Stage (stratigraphy)
Survivin
Transcription factor
YAP1